WillItSurvive
Pharma and healthcare groups · subsidiary of China Resources Pharmaceutical Group Limited (03320.HK) · China

China Resources Sanjiu Medical & Pharmaceutical

State-linked Chinese maker of OTC and TCM drugs under China Resources Pharma group.

Hard to displace
Assessed 25 July 2026 · Evidence as of 25 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 25 July 2026 · Checkable from August 2026 · Every call on the record Checkpoint: H1 2026 results, testing whether Tasly integration profit drag normalizes
The call

Revenue keeps climbing on scale and distribution, but profit growth has stalled as the Tasly deal gets absorbed, not because any AI or big rival is pulling customers away.

CR Sanjiu makes over-the-counter and traditional Chinese medicines sold across China. It is hard to replace because it has government approval, trusted brand names, factories that meet strict rules, and a nationwide store network that took years to build. But the company bought another medicine maker called Tasly in 2025, and combining the two businesses is costing money and cutting profits, even though total sales are growing. What matters most is whether profits start climbing again when the mid-year 2026 results come out around August, because right now sales are jumping 18.6% but profits are actually falling 15.3% compared to last year.

Why
01
AI pressure: None apparent. AI can speed up formulation and R&D work inside the company but no AI product yet touches regulated OTC/TCM manufacturing or distribution. Could AI do the core job? Unlikely.
02
Bigger players: None apparent. No named big rival is taking share; the pressure showing up now is internal, from digesting the Tasly acquisition. Could a giant copy it? No, they are blocked.
03
What protects it. Drug registrations, GMP plants, national distribution network, and brand trust built over decades protect the core OTC and TCM business.
What would change this call
H1 2026 results (due ~August 2026) show net profit vs revenue growth gap. Indicates whether Tasly integration margin drag is normalizing or worsening.
Q3 2026 and FY2026 full-year earnings confirm profit growth reversing toward revenue growth. Shows whether integration costs are being absorbed or continuing to compress profit.
National VBP pricing rounds affecting 999-brand core drugs during 2026. Would show whether procurement policy is eroding core-drug margins beyond integration effects.
Key numbers
  • FY2025 revenue RMB 31.629 billion, up 14.53% (2025-12-31)
  • Q1 2026 net profit down 15.29% YoY despite revenue up 18.62% (2026-03-31)
  • CR Pharma Group holds 63.22% indirect stake (2026-03-20)
Named risks
  • Tasly integration costs suppressing net profit growth despite strong revenue growth (Q1 2026: revenue +18.62%, profit -15.29%). Severity: high
  • National volume-based procurement (VBP) policy could compress core-drug margins over time. Severity: medium
  • Headcount and cost base growth outpacing organic core-999-business profit growth post-Tasly consolidation. Severity: medium
  • Group-level asset reshuffling (e.g., planned divestiture of Hefei Tianmai Biotechnology stake, Feb 2026) signals ongoing portfolio uncertainty. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Yunnan Baiyao GroupcontestingBoth are leading Chinese OTC/TCM incumbents; no share loss evidence found as of 2026
Beijing Tong Ren TangcontestingPeer TCM maker with 17,883 employees; competes in overlapping product categories
Sinopharm Groupgaining onParent CR Pharma ranked below rival in 2025 China pharma sales (~USD35.8bn vs ~USD38bn per Statista, 2026-02-18)
Questions people ask
Is China Resources Sanjiu profitable in 2026?
Yes. CR Sanjiu posted FY2025 net profit of RMB 3.422 billion (up 1.60% YoY) on revenue of RMB 31.629 billion (up 14.53% YoY), as of December 31, 2025. However Q1 2026 net profit fell 15.29% YoY even as revenue rose 18.62%, due to Tasly integration costs.
Could AI replace China Resources Sanjiu?
Unlikely. CR Sanjiu's value sits in regulated drug registrations, decades-old '999' brand trust, GMP manufacturing, and nationwide pharmacy/hospital distribution, none reproducible by AI alone. AI can accelerate TCM formulation research (as seen at sister unit CR Jiangzhong in June 2026) but cannot replace the physical, trust-based business.
Who owns China Resources Sanjiu?
China Resources Sanjiu (000999.SZ) is majority owned by China Resources Pharmaceutical Group Limited (03320.HK), which held 63.22% indirectly as of a March 20, 2026 filing. CR Pharma sits under the state-linked China Resources (Holdings) conglomerate.
Why did China Resources Sanjiu's profit fall in Q1 2026 despite revenue growth?
Q1 2026 revenue grew 18.62% YoY but net profit dropped 15.29% YoY, per a March 21, 2026 summary, driven by integration costs from the RMB 6.2 billion Tasly Pharmaceutical Group acquisition, which closed in March 2025 and is still absorbing costs.
Who is China Resources Sanjiu's biggest competitor?
Its closest domestic OTC/TCM peers are Yunnan Baiyao Group and Beijing Tong Ren Tang, both large diversified Chinese TCM/consumer-health companies. There is no evidence competitors are taking market share from CR Sanjiu; its main pressure is self-inflicted margin drag from the Tasly acquisition, not competitive erosion.
What is the Tasly acquisition and why does it matter for China Resources Sanjiu?
In August 2024 CR Sanjiu agreed to pay RMB 6.2 billion (about USD 869 million) for a 28% controlling stake in peer Tasly Pharmaceutical Group; the deal closed in March 2025. It aims to build a 'one body, two wings' structure across CHC, prescription drugs, and TCM, but has pressured near-term profit margins.
Timeline
  • 2026-03-21Q1 2026 results: revenue up 18.62% YoY but net profit down 15.29% YoY on Tasly integration costs
  • 2026-03-20Filing confirms China Resources Pharmaceutical Group holds 63.22% of CR Sanjiu indirectly
  • 2026-02-06FY2025 preliminary results: revenue RMB 31.629 billion (+14.53%), net profit RMB 3.422 billion (+1.60%)
  • 2025-06Company completes 3-for-10 capital-reserve share conversion
  • 2025-03-27Tasly Pharmaceutical Group acquisition officially closes
  • 2024-08-05CR Sanjiu announces RMB 6.2 billion deal for 28% controlling stake in Tasly Pharmaceutical Group
  • 2010-02Company renamed from Sanjiu Pharmaceutical to China Resources Sanjiu Medical & Pharmaceutical
  • 1999Company founded as Sanjiu Pharmaceutical Co., Ltd.
Revision history
25 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Vertex PharmaceuticalsTenet HealthcareIntuitive Surgical
More in Pharma and healthcare groups →
Sources